Stifel Maintains Buy on Definium Therapeutics, Raises Price Target to $60
Benzinga Newsdesk 4 months ago
Analyst RatingsNewsPrice Target
Stifel analyst Paul Matteis maintains Definium Therapeutics (NASDAQ:DFTX) with a Buy and raises the price target from $30 to $60.
Stifel analyst Paul Matteis maintains Definium Therapeutics (NASDAQ:DFTX) with a Buy and raises the price target from $30 to $60.